HRP20211969T1 - Farmaceutski pripravak karbetocina - Google Patents

Farmaceutski pripravak karbetocina

Info

Publication number
HRP20211969T1
HRP20211969T1 HRP20211969TT HRP20211969T HRP20211969T1 HR P20211969 T1 HRP20211969 T1 HR P20211969T1 HR P20211969T T HRP20211969T T HR P20211969TT HR P20211969 T HRP20211969 T HR P20211969T HR P20211969 T1 HRP20211969 T1 HR P20211969T1
Authority
HR
Croatia
Prior art keywords
carbetocin
pharmaceutical preparation
pharmaceutical
preparation
Prior art date
Application number
HRP20211969TT
Other languages
English (en)
Croatian (hr)
Inventor
Anders Nilsson
Mattias Malm
Kazimierz Wisniewski
Britta Siekmann
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20211969(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of HRP20211969T1 publication Critical patent/HRP20211969T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
HRP20211969TT 2010-09-30 2011-09-29 Farmaceutski pripravak karbetocina HRP20211969T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10251690 2010-09-30
EP17169328.6A EP3222272B1 (en) 2010-09-30 2011-09-29 Pharmaceutical composition of carbetocin

Publications (1)

Publication Number Publication Date
HRP20211969T1 true HRP20211969T1 (hr) 2022-03-18

Family

ID=43478408

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20211969TT HRP20211969T1 (hr) 2010-09-30 2011-09-29 Farmaceutski pripravak karbetocina
HRP20171256TT HRP20171256T1 (hr) 2010-09-30 2011-09-29 Farmaceutski pripravci karbetocina
HRP20250382TT HRP20250382T1 (hr) 2010-09-30 2011-09-29 Farmaceutski pripravak koji sadrži karbetocin

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20171256TT HRP20171256T1 (hr) 2010-09-30 2011-09-29 Farmaceutski pripravci karbetocina
HRP20250382TT HRP20250382T1 (hr) 2010-09-30 2011-09-29 Farmaceutski pripravak koji sadrži karbetocin

Country Status (27)

Country Link
US (4) US9566311B2 (enExample)
EP (5) EP3222272B1 (enExample)
JP (2) JP6038797B2 (enExample)
KR (2) KR101919119B1 (enExample)
CN (4) CN103124554A (enExample)
AU (1) AU2011309762B2 (enExample)
BR (2) BR112013007362B1 (enExample)
CA (1) CA2812510A1 (enExample)
CY (2) CY1119245T1 (enExample)
DK (4) DK4374878T3 (enExample)
ES (4) ES2637988T3 (enExample)
FI (1) FI4374878T3 (enExample)
HR (3) HRP20211969T1 (enExample)
HU (4) HUE056835T2 (enExample)
IL (3) IL225238B (enExample)
JO (3) JO3400B1 (enExample)
LT (3) LT4374878T (enExample)
MX (3) MX390779B (enExample)
NZ (1) NZ609719A (enExample)
PL (4) PL4374878T3 (enExample)
PT (4) PT3222272T (enExample)
RS (3) RS62873B1 (enExample)
RU (2) RU2737264C2 (enExample)
SI (4) SI3222272T1 (enExample)
SM (3) SMT202200034T1 (enExample)
TW (6) TWI650134B (enExample)
WO (1) WO2012042371A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
UA117912C2 (uk) * 2012-05-08 2018-10-25 Ділафор Аб Застосування гепарину або гепарансульфату для лікування післяпологової кровотечі (ппк)
JP6599447B2 (ja) * 2014-09-19 2019-10-30 フェリング ベスローテン フェンノートシャップ プラダー・ウィリー症候群を治療する方法
ES2690140T3 (es) 2014-10-01 2018-11-19 Oxytone Bioscience B.V. Unidad de dosificación farmacéutica sólida de desintegración oral que contiene una sustancia de control del parto
PL3200764T3 (pl) 2014-10-01 2020-12-28 Oxytone Bioscience B.V. Rozpadająca się w jamie ustnej stała farmaceutyczna jednostka dawkowania zawierająca substancję kontrolującą poród
SG11201705591PA (en) 2015-01-07 2017-08-30 Trigemina Inc Magnesium-containing oxytocin formulations and methods of use
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
HRP20250215T1 (hr) 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
CN107773531B (zh) * 2016-08-31 2021-05-04 成都倍特药业股份有限公司 一种马来酸麦角新碱注射液
CN108236601B (zh) * 2016-12-23 2020-04-17 深圳翰宇药业股份有限公司 一种稳定的含卡贝缩宫素的阴道给药的药用组合物及其制备方法
WO2019030412A1 (en) * 2017-08-11 2019-02-14 Ferring B.V. PROCESS FOR PRODUCING PHARMACEUTICAL PREPARATION
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
JP2021515005A (ja) 2018-03-01 2021-06-17 トライジェミナ， インコーポレイテッド 標識オキシトシンならびに製造および使用の方法
CN108721598B (zh) * 2018-07-03 2020-06-05 北京市新里程医药科技有限公司 一种缩宫素原料的制备方法及其药物组合物和制剂
CN114288253B (zh) 2018-09-20 2024-04-02 阿卡蒂亚药品公司 稳定的鼻内卡贝缩宫素制剂
KR20210062648A (ko) 2018-09-20 2021-05-31 레보 테라퓨틱스 인코포레이티드 카르베토신 완제의약품 및 이를 제조하는 방법
CN109745544B (zh) * 2018-11-23 2024-11-08 南京新百药业有限公司 稳定的缩宫素药物组合物及其制备方法
CN113453661A (zh) * 2018-12-21 2021-09-28 艾瑞克有限公司 新组合物
WO2020137880A1 (ja) * 2018-12-27 2020-07-02 国立大学法人北海道大学 オキシトシン誘導体及びその使用
CA3141488A1 (en) 2019-05-22 2020-11-26 Biovie Inc. Formulations of terlipressin
CN110308222A (zh) * 2019-07-17 2019-10-08 武汉赛沃医药科技有限公司 一种卡贝缩宫素原料药有关物质检测方法
CN110403904A (zh) * 2019-07-26 2019-11-05 翔宇药业股份有限公司 卡贝缩宫素注射液及其应用
CN110237230A (zh) * 2019-07-31 2019-09-17 南京康舟医药科技有限公司 一种卡贝缩宫素药物组合物及其制备方法
US20220313774A1 (en) 2019-11-04 2022-10-06 Ferring B.V. Intranasal administration of merotocin for improving lactation
CN111012739A (zh) * 2019-12-04 2020-04-17 长春圣金诺生物制药有限公司 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液
AU2022242768A1 (en) 2021-03-26 2023-10-19 Centre Hospitalier Universitaire De Toulouse Treatment of dysphagia
CN114191388B (zh) * 2021-12-27 2023-06-09 苏州天马医药集团天吉生物制药有限公司 一种卡贝缩宫素制剂的制备方法
CN114712483B (zh) * 2022-05-12 2023-09-29 成都倍特药业股份有限公司 一种麦角新碱缩宫素复方注射液及其制备方法和用途
WO2024211393A2 (en) 2023-04-04 2024-10-10 Tulex Pharmaceuticals Inc. Desmopressin oral compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CN1109558A (zh) * 1994-11-07 1995-10-04 马文亮 装有压力表的双管气筒
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
DE69736140T2 (de) 1997-11-18 2007-04-19 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Pharmazeutische injizierbare Lösungen, die Paracetamol und Kombinationen aus Paracetamol mit anderen Aktivsubstanzen enthalten
US6333313B1 (en) 1998-10-29 2001-12-25 Board Of Regents, The University Of Texas System Clinical use of oxytocin alone or in combination to treat bone disorders
US20070032410A1 (en) 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
JP2001233787A (ja) 2000-02-04 2001-08-28 Patents Exploitation Co Bv 小・中サイズのペプチド含有薬学的組成物
AT409081B (de) 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
ATE556591T1 (de) 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
DE60333857D1 (de) 2002-10-03 2010-09-30 Neuropharmacology Services Llc Oxytocin zur Behandlung von Autismus und Asperger-Syndrom
ATE424215T1 (de) 2003-01-08 2009-03-15 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
CN1938040A (zh) 2003-03-05 2007-03-28 Pr药品有限公司 缩宫素控释制剂及其应用方法
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
WO2008150305A1 (en) * 2007-06-07 2008-12-11 Nastech Pharmaceutical Company Inc. Intranasal carbetocin formulations and methods for the treatment of autism
WO2009005351A1 (en) 2007-07-02 2009-01-08 Sime Darby Malaysia Berhad Vegetable fat blend and edible products containing such a fat blend
ES2319054B1 (es) 2007-08-06 2010-02-12 Gp Pharm S.A. Composicion farmaceutica oral de desmopresina.
SI2260053T1 (sl) * 2008-03-31 2014-08-29 Ferring Bv Analogi oksitocina
CN102281865B (zh) * 2008-10-15 2017-04-05 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用

Also Published As

Publication number Publication date
JP6250770B2 (ja) 2017-12-20
JOP20180103B1 (ar) 2022-03-14
ES2637988T3 (es) 2017-10-18
SI3222272T1 (sl) 2022-01-31
CY1119245T1 (el) 2018-02-14
SI3246018T1 (sl) 2022-02-28
HUE057187T2 (hu) 2022-04-28
BR112013007362A2 (pt) 2016-07-12
JP2017048226A (ja) 2017-03-09
ES3027637T3 (en) 2025-06-16
IL245328B (en) 2022-04-01
PT4374878T (pt) 2025-05-02
PL3222272T3 (pl) 2022-03-07
RS62873B1 (sr) 2022-02-28
SI4374878T1 (sl) 2025-06-30
PL3246018T3 (pl) 2022-05-02
ES2902418T3 (es) 2022-03-28
JP2013543492A (ja) 2013-12-05
HRP20250382T1 (hr) 2025-05-23
HUE056835T2 (hu) 2022-03-28
CY1124924T1 (el) 2023-01-05
US20170106044A1 (en) 2017-04-20
IL245328A0 (en) 2016-06-30
EP2621468B1 (en) 2017-06-14
CN103124554A (zh) 2013-05-29
TW202112389A (zh) 2021-04-01
US20170106043A1 (en) 2017-04-20
JOP20180102A1 (ar) 2019-01-30
CA2812510A1 (en) 2012-04-05
US9566311B2 (en) 2017-02-14
WO2012042371A2 (en) 2012-04-05
TW201605465A (zh) 2016-02-16
EP3222272B1 (en) 2021-11-03
IL245326A0 (en) 2016-06-30
TW201605466A (zh) 2016-02-16
US20230124105A1 (en) 2023-04-20
TWI746951B (zh) 2021-11-21
RU2604690C2 (ru) 2016-12-10
EP3936117A1 (en) 2022-01-12
HRP20171256T1 (hr) 2017-10-20
CN107080832B (zh) 2021-05-07
LT3222272T (lt) 2021-12-27
EP3246018A1 (en) 2017-11-22
DK3246018T3 (da) 2022-01-17
KR101919119B1 (ko) 2018-11-15
HUE070972T2 (hu) 2025-07-28
DK4374878T3 (da) 2025-05-05
JO3400B1 (ar) 2019-10-20
TWI680773B (zh) 2020-01-01
KR20180123599A (ko) 2018-11-16
RS66759B1 (sr) 2025-05-30
IL225238B (en) 2018-07-31
CN107412728A (zh) 2017-12-01
EP4374878A2 (en) 2024-05-29
DK2621468T3 (en) 2017-09-11
ES2905561T3 (es) 2022-04-11
RU2016143751A3 (enExample) 2020-01-16
FI4374878T3 (fi) 2025-05-16
TWI532507B (zh) 2016-05-11
SI2621468T1 (sl) 2017-10-30
AU2011309762B2 (en) 2014-07-17
PT3222272T (pt) 2022-01-27
TW201219051A (en) 2012-05-16
MX2013003365A (es) 2013-07-29
LT2621468T (lt) 2017-11-27
BR112013007362B1 (pt) 2021-05-25
EP3222272A1 (en) 2017-09-27
EP4374878A3 (en) 2024-07-24
JOP20180103A1 (ar) 2019-01-30
SMT202200034T1 (it) 2022-03-21
BR122021001123B1 (pt) 2021-05-18
TWI661834B (zh) 2019-06-11
IL245326B (en) 2021-04-29
PT3246018T (pt) 2022-01-13
SMT202500165T1 (it) 2025-05-12
CN104906032A (zh) 2015-09-16
TW201729797A (zh) 2017-09-01
EP3246018B1 (en) 2021-11-03
US20130210746A1 (en) 2013-08-15
TWI650134B (zh) 2019-02-11
MX352949B (es) 2017-12-15
MX395271B (es) 2025-03-21
PL4374878T3 (pl) 2025-06-09
RU2013112666A (ru) 2014-11-10
KR20130136467A (ko) 2013-12-12
PT2621468T (pt) 2017-09-08
JOP20180102B1 (ar) 2022-03-14
NZ609719A (en) 2014-07-25
SMT201700420T1 (it) 2017-11-15
HUE034367T2 (en) 2018-02-28
RU2737264C2 (ru) 2020-11-26
PL2621468T3 (pl) 2017-11-30
LT4374878T (lt) 2025-04-25
RS56220B1 (sr) 2017-11-30
CN107080832A (zh) 2017-08-22
TW201940188A (zh) 2019-10-16
IL225238A0 (en) 2013-06-27
DK3222272T3 (da) 2022-01-24
EP2621468A2 (en) 2013-08-07
KR102102664B1 (ko) 2020-04-22
MX390779B (es) 2025-03-21
RU2016143751A (ru) 2018-12-18
WO2012042371A3 (en) 2013-04-04
AU2011309762A1 (en) 2013-04-04
EP4374878B1 (en) 2025-02-12
JP6038797B2 (ja) 2016-12-07
TWI750934B (zh) 2021-12-21
HK1246170A1 (en) 2018-09-07

Similar Documents

Publication Publication Date Title
HRP20211969T1 (hr) Farmaceutski pripravak karbetocina
SMT201600350B (it) Composizioni farmaceutiche
SMT201700008B (it) Composizione farmaceutica
EP2549986A4 (en) MACROPHONE LEAVE TO MULTIPLE OBJECTIVES
LT2603232T (lt) Stabilios linaklotido vaisto formos
GT201200303A (es) Formulaciones farmacéuticas
FI20105639A0 (fi) Mikroselluloosan valmistus
EP2552212A4 (en) IMPROVED FORMULATION
IL225346A0 (en) Serum preparation
EP2531023A4 (en) IMPROVED FORMULATION
DK2635269T3 (da) Kombinationspræparat
DK2444068T3 (da) Brimonidingelpræparat
CO6801722A2 (es) Composiciones farmacéuticas
BR112014015885A2 (pt) preparação farmacêutica
FR2955473B1 (fr) Structure de presentoir
HRP20180567T1 (hr) Farmaceutski pripravak omeprazola
BR112013008074A2 (pt) combinações farmacêuticas
SMT201500005B (it) Composizione framaceutica inalabile
BR112013014291A2 (pt) formulação lipossômica de calcetrapib
HUE036784T2 (hu) Alisporivirt tartalmazó gyógyászati készítmények
BR112012029461A2 (pt) composição farmacêutica contendo solifenacina
BR112012029887A2 (pt) composição farmacêutica
EP2654772A4 (en) CYCLIC PEPTIDES THAN CRF ANTAGONISTS
FR2956419B1 (fr) Elements de construction calorifuges
FR2955136B1 (fr) Arret de vantail